TAKEDA PHARMACEUTIC-SP ADR (TAK) Stock News
NYSE:TAK - New York Stock Exchange, Inc. - US8740602052 - ADR - Currency: USD
TAK Latest News, Press Relases and Analysis
TAK vs. DSNKY: Which Stock Is the Better Value Option?
TAK vs. DSNKY: Which Stock Is the Better Value Option?
UK's Health Agency Endorses Pfizer's Blood Cancer Combo Therapy As First For Untreated Hodgkin Lymphoma Patients
NICE recommended Pfizer's Adcetris for NHS use in advanced Hodgkin lymphoma, citing strong trial data and a new discount agreement with Takeda.
Mentions: PFE
TAK vs. DSNKY: Which Stock Should Value Investors Buy Now?
TAK vs. DSNKY: Which Stock Is the Better Value Option?
Chinese Biotech Ascentage Pharma's Valuation Driven By Late-Stage De-Risked Assets: JPMorgan
JP Morgan sees strong growth for Ascentage Pharma, citing its late-stage cancer drugs. The biotech's 2024 sales surged 342% YoY, driven by a Takeda payment.
Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera
Mentions: PTGX
La Agencia Europea de Medicamentos aprueba una opción adicional de administración subcutánea de TAKHZYRO®
La Agencia Europea de Medicamentos (EMA) ha aprobado una opción adicional de administración subcutánea de TAKHZYRO® (lanadelumab) para pacientes de 12 años o...
Die Europäische Arzneimittelagentur (EMA) hat eine zusätzliche Option zur subkutanen Verabreichung von TAKHZYRO® (Lanadelumab) für Patienten ab 12 Jahren mit wiederkehrenden Attacken des hereditären Angioödems (HAE) genehmigt
/PRNewswire/ -- Takeda (TSE:4502/NYSE:TAK) gab heute bekannt, dass die EMA eine zusätzliche 2-ml-Fertigpen-Option für TAKHZYRO® (Lanadelumab) zur subkutanen...
L'Agence européenne des médicaments (EMA) a approuvé une option supplémentaire d'administration sous-cutanée pour TAKHZYRO® (lanadelumab) chez les patients âgés de 12 ans et plus souffrant d'attaques récurrentes d'angio-œdème héréditaire (AOH).
/PRNewswire/ -- Takeda (TSE: 4502) (NYSE: TAK) annonce aujourd'hui que l'EMA a approuvé une option supplémentaire de stylo prérempli de 2 ml pour TAKHZYRO®...
The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE)
/PRNewswire/ -- Takeda (TSE: 4502) (NYSE: TAK) announced today that the EMA has approved an additional 2 mL pre-filled pen option for TAKHZYRO® (lanadelumab)...
Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026
Takeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year Outlook, Forecasting Revenue and Core Operating Profit Margin Growth
Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)
Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas
Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics
HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan
HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda
— US$20 million payment based on sales of FRUZAQLA® in metastatic colorectal cancer —
Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook
Takeda and Boston Medical Center Announce Innovative Collaboration to Help Tackle Decarbonization Across Health Care Ecosystem
Joint Venture Company Established for Incubation of Early Drug Discovery Programs; Investment from Takeda, Astellas and Sumitomo Mitsui Banking
/PRNewswire/ -- Ciconia Bioventures Inc. (Representative Director, Founder CEO: Toshio Fujimoto, "Ciconia") today announced its establishment as a joint...
Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer
HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda
